Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Summary

The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung disease. Its use in this study is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.

Timeline

Start

2015-06-22

Primary completion

2018-06-08

Completion

2019-06-08

Drugs

Indications